Aegerion to prep Japanese lomitapide NDA on new data

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) said lomitapide met the primary endpoint in a Japanese open-label Phase III trial to treat homozygous familial hypercholesterolemia (hoFH).

The primary endpoint of the nine-patient trial was the mean percent change in LDL-C at the maximum tolerated dose compared to baseline after 26 weeks of treatment. ...